Chemotherapy and pembrolizumab combination significantly improves outcomes in advanced non-small-cell lung cancer

The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers reported at the ESMO 2016 Congress in Copenhagen today.Pembrolizumab is a class of immunotherapeutic anti-cancer drugs called checkpoint inhibitors, which target the mechanism the tumor uses to shut down the body’s … Continue reading Chemotherapy and pembrolizumab combination significantly improves outcomes in advanced non-small-cell lung cancer